For the quarter ended September 30, 2010, the Company's marketing and selling expenses increased 56%, or $31,000, to $86,000 compared to $55,000 for the same period in 2009. This increase was primarily due to marketing and sales brokerage related expenses associated with the planned distribution of the nutritional products.
General and administrative expenses decreased 47%, or $571,000, to $650,000 for the three months ended September 30, 2010, compared to $1.2 million for the same period in 2009, primarily due to lower personnel-related expenses through personnel reductions.
Research and development expenses decreased 55%, or $315,000, to $257,000 for the three months ended September 30, 2010, compared to $572,000 for the same period in 2009, primarily due to reductions in personnel and other expenses reflecting the deferral of development activities for certain product candidates.
Net loss decreased 45%, or $716,000, to $869,000 for the three months ended September 30, 2010, compared to $1.6 million for the same period in 2009. The decrease was primarily due to lower overall operating expenses.
As of September 30, 2010, the Company had approximately $2.4 million in cash and cash equivalents, and $275,000 in restricted cash. Based on its current operating plan, the Company anticipates that existing cash and cash equivalents, together with expected royalties from third parties, will be sufficient to fund operations into the second quarter of 2011, unless unforeseen events arise that negatively impact liquidity.
Nine Months 2010 compared to Nine Months 2009 Financial ResultsTotal revenues decreased 23%, or $151,000, to $513,000 for the nine months ended September 30, 2010, compared to $664,000 for the same period in 2009. This decrease is primarily due to a reduction in royalty revenue from the Company's relati
|SOURCE SCOLR Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved